Demonstrating Cost Effectiveness of Clinical NGS is Key to Payor Reimbursement, Hospital Uptake | GenomeWeb

By Monica Heger

One major hurdle in bringing next-generation sequencing into the clinic is how it will be received by payors and hospitals.

In a webinar hosted by Illumina this week, Trisha Brown, vice president of clinical affairs at Medco subsidiary DNA Direct, said that demonstrating the technology's cost effectiveness will be key to gaining reimbursement and encouraging hospital uptake.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.